Intech Investment Management LLC Has $697,000 Position in Zimmer Biomet Holdings, Inc. $ZBH

Intech Investment Management LLC cut its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 36.0% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 7,640 shares of the medical equipment provider’s stock after selling 4,294 shares during the period. Intech Investment Management LLC’s holdings in Zimmer Biomet were worth $697,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. Accent Capital Management LLC bought a new position in Zimmer Biomet in the 1st quarter worth approximately $35,000. Zions Bancorporation National Association UT bought a new stake in shares of Zimmer Biomet in the first quarter valued at approximately $48,000. Hilltop National Bank acquired a new stake in shares of Zimmer Biomet in the second quarter worth $42,000. Brooklyn Investment Group increased its position in Zimmer Biomet by 45.9% during the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock worth $52,000 after acquiring an additional 145 shares during the period. Finally, True Wealth Design LLC raised its stake in Zimmer Biomet by 875.0% during the 2nd quarter. True Wealth Design LLC now owns 468 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 420 shares during the last quarter. Institutional investors own 88.89% of the company’s stock.

Insider Activity

In related news, SVP Lori Winkler sold 1,500 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. This represents a 18.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.39% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, October 8th. Royal Bank Of Canada reduced their target price on shares of Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, November 6th. Johnson Rice set a $112.00 price target on Zimmer Biomet in a research note on Wednesday, November 5th. BTIG Research cut their price target on Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Finally, Redburn Partners set a $130.00 price objective on Zimmer Biomet in a report on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $109.00.

Zimmer Biomet Stock Up 0.6%

NYSE ZBH opened at $97.66 on Thursday. Zimmer Biomet Holdings, Inc. has a 1-year low of $85.33 and a 1-year high of $114.44. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54. The stock’s 50 day moving average is $96.94 and its two-hundred day moving average is $96.80. The company has a market capitalization of $19.35 billion, a price-to-earnings ratio of 23.76, a PEG ratio of 2.29 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. During the same period in the prior year, the company posted $1.74 earnings per share. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.